Table 4. Postoperative clinical data of recipients with or without post-OLT AKI.
| Factors | Non-AKI (n = 4288) (%) | AKI (n = 194) (%) | P value |
|---|---|---|---|
| Postoperative complications | |||
| Intraperitoneal hemorrhage | 194 (4.52) | 64 (32.99) | <0.001 |
| Biliary complications | 198 (4.62) | 10 (5.15) | 0.728 |
| Vascular complications | 152 (3.54) | 17 (8.76) | <0.001 |
| Abnormal graft function | 71 (1.66) | 55 (28.35) | <0.001 |
| Postoperative infection | 677 (15.79) | 87 (44.85) | <.001 |
| Diabetes | 537 (12.52) | 42 (21.65) | <0.001 |
| Hypertension | 144 (3.36) | 12 (6.19) | 0.036 |
| New-onset diabetes | 430 (10.03) | 32 (16.49) | 0.004 |
| New-onset hypertension | 94 (2.19) | 6 (3.09) | 0.406 |
| Cytomegalovirus infection | 51 (1.19) | 2 (1.03) | 0.847 |
| Pleural effusion | 989 (23.06) | 95 (48.97) | <0.001 |
| Pneumonedema | 40 (0.93) | 20 (10.31) | <0.001 |
| Intra-abdominal abscess | 481 (11.22) | 64 (32.99) | <0.001 |
| Initial induction of CNI | |||
| Tacrolimus | 2680 (62.51) | 146 (75.02) | 0.015 |
| Cyclosporine | 391 (9.11) | 25 (13.04) | 0.027 |
| Average CNI trough level (ng/ml) | |||
| Tacrolimus | 9.2 (8.8, 9.6) | 10.3 (9.8, 10.7) | 0.008 |
| Cyclosporine | 178.5 (172, 185) | 174.1 (162, 181) | 0.324 |
| Overexposure to CNI | 527 (12.30) | 93 (48.14) | <0.001 |
| MMF use | 3044 (71.08) | 81 (42.10) | <0.001 |
| Dobutamine (days) | 1.2 (0.0, 2.4) | 3.5 (0.8, 6.2) | <0.001 |
| Dopamine (days) | 3.2 (1.1, 5.3) | 5.4 (3.5, 7.3) | <0.001 |
| Length of hospital stay (days) | 25 (18,35) | 16 (6,34.5) | <0.001 |
| Follow-up duration (month) | 3.82 (0.92, 10.66) | 0.72 (0.2, 3.88) | <0.001 |